Why the study?
It was unknown whether PCSK9 inhibition could represent a therapeutic strategy in calcific aortic valve stenosis.
Does genetic or in vitro PCSK9 inhibition reduce the prevalence or progression of calcific aortic valve stenosis?
Does genetic or in vitro PCSK9 inhibition reduce the prevalence or progression of calcific aortic valve stenosis?
Genetic and in vitro evidence suggests that PCSK9 inhibition may represent a viable therapeutic strategy to reduce the risk and progression of calcific aortic valve stenosis.
Answers are grounded in this paper and cite their sources.
PCSK9 inhibition may lower CAVS risk; leaves open confirmation in randomized trials.
The authors investigated whether PCSK9 inhibition could represent a therapeutic strategy in calcific aortic valve stenosis (CAVS). A meta-analysis of 10 studies was performed to determine the impact of the PCSK9 R46L variant on CAVS, and the authors found that CAVS was less prevalent in carriers of this variant (odds ratio: 0.80 [95% confidence interval: 0.70 to 0.91]; p = 0.0011) compared with noncarriers. PCSK9 expression was higher in the aortic valves of patients CAVS compared with control patients. In human valve interstitials cells submitted to a pro-osteogenic medium, PCSK9 levels increased and a PCSK9 neutralizing antibody significantly reduced calcium accumulation.
No takes yet. Share an insight, caveat, or question.
Perrot et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: